ArticleEClinicalMedicine2019
Cell and Gene Therapy Trials: Are We Facing an 'Evidence Crisis'?
Article in EClinicalMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions.Paediatric drugs · 2024Article
- Challenges for gene therapy in the financial sustainability of health systems: a scoping review.Orphanet journal of rare diseases · 2024Article
- Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.JAMA network open · 2022Article
- The Randomised Controlled Trial at the Intersection of Research Ethics and Innovation.Pharmaceutical medicine · 2022Article
- Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment.Frontiers in public health · 2022Review
- Current landscape of clinical development and approval of advanced therapies.Molecular therapy. Methods & clinical development · 2021Review
- Evidence generation and reproducibility in cell and gene therapy research: A call to action.Molecular therapy. Methods & clinical development · 2021Article
- Cellular therapies in organ transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2021Review
- RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More!Frontiers in medicine · 2021Article
- Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward.Frontiers in bioengineering and biotechnology · 2021Article
- Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals.Molecular therapy. Methods & clinical development · 2020Article
- CAR T-cell product performance in haematological malignancies before and after marketing authorisation.The Lancet. Oncology · 2020Review
- A few ethical issues in translational research for gene and cell therapy.Journal of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.